$CURR

Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 4, 2025 - Blueberries Medical (OTC:BBRRF), Belgravia Hartford Cap (OTC:BLGVF)

4Front Ventures FFNTF shares closed up 60.00% at $0.00 Belgravia Hartford Cap BLGVF shares closed up 22.01% at $0.25 Auxly Cannabis Group CBWTF shares closed up 14.50% at $0.09 Currenc Group CURR shares closed up 14.27% at $1.04 Tilray Brands TLRY shares closed up 10.20% at $0.54

Original reporting
Benzinga · Benzinga Insights
Published Jul 4, 2025, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 4, 2025, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 4, 2025 - Blueberries Medical (OTC:BBRRF), Belgravia Hartford Cap (OTC:BLGVF) — source image
Decision brief

The 30-second read

$CURRBullishMed
01

Why it matters

The recent bullish momentum could signal a shift in market sentiment, potentially attracting more capital and driving further gains.

02

Market read

The sector is currently experiencing bullish sentiment, driven by positive news and stock movements, which could influence investor behavior and sector valuations.

03

What to watch

Regulatory changes, market saturation, and macroeconomic factors could impact sector performance; these risks should be factored into trading decisions.

Timing: Immediate; news published on July 4, 2025, indicates current sector momentum.

Background

The cannabis sector has experienced increased investor interest due to legalization trends and industry consolidation.

Company-level read

Ticker impact

$CURRBullishMedium confidence
Context

Moderate relevance; Currency Group's 14.3% rise indicates positive sector sentiment.

Expected impact

Potential for short-term gains, but with caution due to moderate increase.

Evidence & confidence

The rise aligns with sector trends, but further confirmation needed for sustained moves.

$TLRYBullishHigh confidence
Context

High relevance; Tilray Brands increased by 10.2%, a significant move within the cannabis industry.

Expected impact

Likely continuation of upward trend if sector momentum persists.

Evidence & confidence

The notable increase in a leading industry player supports ongoing bullish momentum.

Market effects

The positive sentiment across multiple cannabis stocks suggests a bullish phase in the cannabis sector, potentially influencing related industries such as retail, biotech, and agriculture.

Primarily affecting North American markets, given the OTC listings and regional focus.

Moderate; while the sector is growing, broader global market effects are limited at this stage.

Counterpoint

The recent surge may be a short-term correction or a speculative bubble; caution is advised before committing large positions.

Key entities

  • Blueberries Medical

    A cannabis company listed OTC, experiencing significant share price increase.

  • Belgravia Hartford Cap

    A financial entity with exposure to cannabis investments.

  • Auxly Cannabis Group

    A cannabis producer showing positive stock movement.

  • Currency Group

    A financial services firm with cannabis-related assets.

  • Tilray Brands

    A major cannabis producer and distributor.

Related articles

$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.

$TLRYMed

Tilray Brands reports record US$915.5M revenue in Fiscal 2026

Tilray Brands reported record fiscal 2026 revenue of US$915.5M, up 11% from US$821.3M, driven by cannabis, beverage, distribution and wellness. Beverage net revenue rose 6% to US$254.0M, with Q4 beverage revenue up 61% to US$105M. Adjusted EBITDA increased to US$61.1M. Tilray completed a £33M BrewDog acquisition in March. It forecasts fiscal 2027 adjusted EBITDA of US$68M to US$75M.

$TLRYMedAI 8/10

Tilray Brands Q4 revenue beats estimates by 10.7%, shares rise 2.23%

Tilray Brands reported Q4 net revenue of $281.7 million for the period ended May 31, up 10.7% versus the $254.53 million consensus estimate, and shares rose 2.23% to $4.12 after hours. Adjusted EPS was $0.05, missing the $0.21 consensus. For FY26, net revenue rose 11% to $915.5 million; adjusted EBITDA increased to $61.1 million.